Class III b-tubulin overexpression in gynecologic tumors: Implications for the choice of microtubule targeted agents?

Expert Review of Anticancer Therapy

Volumn 13, Issue 1, 2013, Pages 63-74

  English, Diana P ^a   Roque, Dana M ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biologic aggressiveness; class III b tubulin; epothilones; paclitaxel resistance; taxanes; tubulin binding agents

Indexed keywords

BETA TUBULIN; BETA TUBULIN CLASS III; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; EVEROLIMUS; GEMCITABINE; IXABEPILONE; MICROTUBULE PROTEIN; OCTREOTIDE; PACLITAXEL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ANOREXIA; BETA TUBULIN CLASS III GENE; BINDING AFFINITY; BINDING SITE; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOSARCOMA; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLEAR CELL CARCINOMA; COLITIS; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTESTINE OBSTRUCTION; LEIOMYOSARCOMA; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; ONCOGENE; OVARIAN CLEAR CELL CARCINOMA; OVARY CANCER; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE SEROUS CARCINOMA; UTERINE TUBE TUMOR; UTERUS CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL NEOPLASMS, FEMALE; HUMANS; MICROTUBULES; MOLECULAR TARGETED THERAPY; TUBULIN; TUBULIN MODULATORS;

EID: 84871603385     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.158     Document Type: Review

References (107)

1. Baas PW, Karabay A, Qiang L. Microtubules cut and run. Trends Cell Biol. 15(10), 518-524 (2005).
2. Wilson L, Panda D, Jordan MA. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct. 24(5), 329-335 (1999).
3. Cooper G. The Cell: A Molecular Approach (2nd edition). Microtubules, Sinauer Associates, MA, USA (2000).
4. Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 12(12), 773-786 (2011).
5. Roll-Mecak A, McNally FJ. Microtubule-severing enzymes. Curr. Opin. Cell Biol. 22(1), 96-103 (2010).
6. Verhey KJ, Hammond JW. Traffic control: regulation of kinesin motors. Nat. Rev. Mol. Cell Biol. 10(11), 765-777 (2009).
7. Panda D, Miller HP, Banerjee A, Ludueña RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl Acad. Sci. USA 91(24), 11358-11362 (1994).
8. Luchko T, Huzil JT, Stepanova M, Tuszynski J. Conformational analysis of the carboxy-terminal tails of human β-tubulin isotypes. Biophys. J. 94(6), 1971-1982 (2008).
9. Khawaja S, Gundersen GG, Bulinski JC. Enhanced stability of microtubules enriched in detyrosinated tubulin is not a direct function of detyrosination level. J. Cell Biol. 106(1), 141-149 (1988).
10. Ludueña RF. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. 178, 207-275 (1998).
11. Lopata MA, Cleveland DW. In vivo microtubules are copolymers of available β-tubulin isotypes: localization of each of six vertebrate β-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens. J. Cell Biol. 105(4), 1707-1720 (1987).
12. Bhattacharya R, Cabral F. A ubiquitous β-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol. Biol. Cell 15(7), 3123-3131 (2004).
13. Keith CH. Neurite elongation is blocked if microtubule polymerization is inhibited in PC12 cells. Cell Motil. Cytoskeleton 17(2), 95-105 (1990).
14. Jaffrézou JP, Dumontet C, Derry WB et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol. Res. 7(10-11), 517-527 (1995).
15. Kanakkanthara A, Teesdale-Spittle PH, Miller JH. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics. Anticancer. Agents Med. Chem. (2012).
16. Kanakkanthara A, Northcote PT, Miller JH. bII-tubulin and bIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol. Cancer Ther. 11(2), 393-404 (2012).
17. Natarajan K, Senapati S. Understanding the basis of drug resistance of the mutants of aß-tubulin dimer via molecular dynamics simulations. PLoS ONE 7(8), e42351 (2012).
18. Giannakakou P, Sackett DL, Kang YK et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272(27), 17118-17125 (1997).
19. Hara T, Ushio K, Nishiwaki M et al. A mutation in β-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol. Int. 34(2), 177-184 (2010).
20. Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9(2), 168-175 (2008).
21. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry 36(12), 3554-3562 (1997).
22. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 56(1), 45-56 (2003).
23. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19(1-2), 59-65 (2000).
24. Mozzetti S, Ferlini C, Concolino P et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11(1), 298-305 (2005).
25. Raspaglio G, Filippetti F, Prislei S et al. Hypoxia induces class III β-tubulin gene expression by HIF-1 alpha binding to its 3́ flanking region. Gene 409(1-2), 100-108 (2008).
26. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10(3), 194-204 (2010).
27. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 5, 117-124 (2011).
28. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov. Today 6(22), 1153-1164 (2001).
29. Gajewski MM, Alisaraie L, Tuszynski JA. Peloruside, laulimalide, and noscapine interactions with β-tubulin. Pharm. Res. 29(11), 2985-2993 (2012).
30. Risinger AL, Jackson EM, Polin LA et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 68(21), 8881-8888 (2008).
31. Li J, Risinger AL, Peng J, Chen Z, Hu L, Mooberry SL. Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers. J. Am. Chem. Soc. 133(47), 19064-19067 (2011).
32. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5́-triphosphate or microtubule-associated proteins. Biochemistry 20(11), 3247-3252 (1981).
33. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77(3), 1561-1565 (1980).
34. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 32(6), 1220-1262 (2012).
35. Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest. 100(5), 1282-1293 (1997).
36. Ferlini C, Raspaglio G, Cicchillitti L et al. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr. Cancer Drug Targets 7(8), 704-712 (2007).
37. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The βI/βIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J. 273(14), 3301-3310 (2006).
38. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325-2333 (1995).
39. Lee FY, Smykla R, Johnston K et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 63(2), 201-212 (2009).
40. Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist 16(10), 1349-1358 (2011).
41. Santin AD, Bellone S, Van Stedum S et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7), 1391-1397 (2005).
42. Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 108(1), 3-9 (2008).
43. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a Phase I, open-label, dose-escalation study. J. Clin. Oncol. 27(19), 3097-3103 (2009).
44. Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin. Investig. Drugs 20(1), 107-117 (2011).
45. De Geest K, Blessing JA, Morris RT et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J. Clin. Oncol. 28(1), 149-153 (2010).
46. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther. 8(1), 17-25 (2009).
47. Banerjee A. Increased levels of tyrosinated alpha-, β(III)-, and β(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 293(1), 598-601 (2002).
48. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of β(III)-and β(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56(11), 2584-2589 (1996).
49. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer 77(4), 562-566 (1998).
50. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22(11), 2159-2166 (2004).
51. Mozzetti S, Iantomasi R, De Maria I et al. Molecular mechanisms of patupilone resistance. Cancer Res. 68(24), 10197-10204 (2008).
52. Aoki D, Oda Y, Hattori S et al. Overexpression of class III β-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin. Cancer Res. 15(4), 1473-1480 (2009).
53. Gan PP, Pasquier E, Kavallaris M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67(19), 9356-9363 (2007).
54. Mariani M, Zannoni GF, Sioletic S et al. Gender influences the class III and V b-tubulin ability to predict poor outcome in colorectal cancer. Clin. Cancer Res. 18(10), 2964-2975 (2012).
55. Leskelä S, Leandro-García LJ, Mendiola M et al. The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer 18(1), 85-95 (2011).
56. Marchini S, Cavalieri D, Fruscio R et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 12(3), 273-285 (2011).
57. Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil. Cytoskeleton 66(7), 378-388 (2009).
58. De Donato M, Mariani M, Petrella L et al. Class III b-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J. Cell. Physiol. 227(3), 1034-1041 (2012).
59. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed Müllerian tumors of the ovary. Gynecol. Oncol. 85(3), 459-463 (2002).
60. Thigpen JT, Blessing JA, Orr JW Jr, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat. Rep. 70(2), 271-274 (1986).
61. Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. 7(3), 253-256 (1984).
62. Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol. Oncol. 83(2), 268-270 (2001).
63. Sutton G, Brunetto VL, Kilgore L et al. A Phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol. Oncol. 79(2), 147-153 (2000).
64. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H; Gynecologic Oncology Group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group Study. Gynecol. Oncol. 96(3), 630-634 (2005).
65. Wolfson AH, Brady MF, Rocereto T et al. A Gynecologic Oncology Group randomized Phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol. Oncol. 107(2), 177-185 (2007).
66. Homesley HD, Filiaci V, Markman M et al.; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(5), 526-531 (2007).
67. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the Memorial Sloan-Kettering Cancer Center experience. Gynecol. Oncol. 105(3), 657-661 (2007).
68. Gupta D, Owers RL, Kim M et al. A Phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol. Oncol. 113(3), 327-330 (2009).
69. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int. J. Gynecol. Cancer 20(5), 888-894 (2010).
70. Carrara L, Guzzo F, Roque DM et al. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-β-III expression. Gynecol. Oncol. 125(1), 231-236 (2012).
71. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a Phase II study. J. Clin. Oncol. 19(20), 4048-4053 (2001).
72. Vandenput I, Capoen A, Coenegrachts L et al. Expression of ERCC1, p53, and class III b-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study. Int. J. Gynecol. Cancer 21(6), 1071-1077 (2011).
73. Zhu C, Luo J, Shi H, Xie X, Ding Z. Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer. Eur. J. Gynaecol. Oncol. 30(5), 514-517 (2009).
74. Ferrandina G, Martinelli E, Zannoni GF et al. Expression of class III β tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol. Oncol. 104(2), 326-330 (2007).
75. Hamilton CA, Cheung MK, Osann K et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 94(5), 642-646 (2006).
76. Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol. Oncol. 91(3), 463-469 (2003).
77. Podratz KC, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol. Oncol. 91(3), 461-462 (2003).
78. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol. 6(2), 93-108 (1982).
79. Sovak MA, Hensley ML, Dupont J et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol. Oncol. 103(2), 451-457 (2006).
80. Ozols RF, Bundy BN, Greer BE et al.; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21(17), 3194-3200 (2003).
81. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin. Obstet. Gynecol. 39(3), 686-695 (1996).
82. Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C. Class III b-tubulin (TUBB3): more than a biomarker in solid tumors? Curr. Mol. Med. 11(9), 726-731 (2011).
83. Sève P, Reiman T, Dumontet C. The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67(2), 136-143 (2010).
84. Tommasi S, Mangia A, Lacalamita R et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int. J. Cancer 120(10), 2078-2085 (2007).
85. Ferrandina G, Zannoni GF, Martinelli E et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12(9), 2774-2779 (2006).
86. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin. Breast Cancer 11(3), 139-145 (2011).
87. Lee FY, Covello KL, Castaneda S et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin. Cancer Res. 14(24), 8123-8131 (2008).
88. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther. Adv. Med. Oncol. 3(1), 11-25 (2011).
89. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol. Oncol. 126(3), 481-490 (2012).
90. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol. 70(2), 255-258 (1998).
91. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol. Oncol. 32(3), 342-349 (1989).
92. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol. Oncol. 32(1), 65-71 (1989).
93. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 47(2), 159-166 (1992).
94. Umezu T, Shibata K, Kajiyama H et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III β-tubulin. Int. J. Gynecol. Pathol. 27(2), 207-212 (2008).
95. Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J. Gynecol. Oncol. 22(3), 183-187 (2011).
96. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21(9), 1866-1873 (2003).
97. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10(4), 1289-1298 (2004).
98. Hensley ML, Dizon D, Derosa F et al. A Phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest. New Drugs 25(4), 335-341 (2007).
99. Agrawal M, Edgerly M, Fojo T, Kotz H. Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecol. Oncol. 90(1), 96-99 (2003).
100. Rubin EH, Rothermel J, Tesfaye F et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. 23(36), 9120-9129 (2005).
101. Forster M, Kaye S, Oza A et al. A Phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin. Cancer Res. 13(14), 4178-4184 (2007).
102. Schelman W, Morgan-Meadows S, Bailey H et al. A Phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 62(4), 727-733 (2008).
103. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J. Clin. Oncol. 27(19), 3104-3108 (2009).
104. Garcia AA, Blessing JA, Nolte S, Mannel RS; Gynecologic Oncology Group. A Phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol. Oncol. 111(1), 22-26 (2008).
105. Colombo N, Kutarska E, Dimopoulos M et al. Randomized, open-label, Phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. 30(31), 3841-3847 (2012).
106. Ohishi Y, Oda Y, Basaki Y et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol. Oncol. 105(3), 586-592 (2007).
107. Gao S, Zhao X, Lin V et al. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour Biol. 33(5), 1759-1765 (2012).